INP 104

Drug Profile

INP 104

Alternative Names: INP104

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Impel NeuroPharma
  • Class Antimigraines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Migraine

Most Recent Events

  • 20 Jan 2017 Phase-II clinical trials in Migraine (Intranasal) (Impel NeuroPharma pipeline, January 2017) before January 2017
  • 05 Oct 2015 Clinical trials in Migraine (Late-stage disease, Treatment-resistant) in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top